CHINA PHARMA<1093> - Results Announcement
China Pharmaceutical Enterprise and Investment Corporation Limited
announced on 19/4/2001:
(stock codes: Ord: 1093 & War: 837)
Year end date: 31/12/2000
Currency: HKD (Audited)
(Audited) Last
Current Corresponding
Period Period
from 1/1/2000 from 1/1/1999
to 31/12/2000 to 31/12/1999
Turnover : 995,096,000 821,321,000
Profit/(Loss) from Operations : 128,639,000 166,751,000
Finance cost : (29,843,000) (29,407,000)
Share of Profit/(Loss) of Associates : (290,000) -
Share of Profit/(Loss) of
Jointly Controlled Entities : 3,779,000 7,210,000
Profit/(Loss) after Tax & MI : 80,473,000 142,022,000
% Change over Last Period : -43%
EPS/(LPS)-Basic : 6.49 cents 12.52 cents
-Diluted : 6.40 cents 12.41 cents
Extraordinary (ETD) Gain/(Loss) : - -
Profit/(Loss) after ETD Items : 80,473,000 142,022,000
Final Dividend per Share : Nil 3.3 cents
(Specify if with other options) : - -
B/C Dates for Final Dividend : N/A
Payable Date : N/A
B/C Dates for (-) General Meeting : N/A
Other Distribution for Current Period : -
B/C Dates for Other Distribution : N/A
Remarks:
1. Earnings per share
The calculation of the basic and diluted earnings per share is based on
the following data:
2000 1999
Profit attributable to shareholders HK$80,473,000 HK$142,022,000
============== ==============
Weighted average number of ordinary
shares for the purposes of basic
earnings per share 1,240,429,301 1,134,591,763
Effect of dilutive potential ordinary
shares in respect of share option 16,000,000 9,560,976
-------------- -------------
Weighted average number of ordinary
shares for the purposes of diluted
earnings per share 1,256,429,301 1,144,152,739
============= ==============
The computation of diluted earnings per share does not assume the exercise
of the Company's outstanding warrants as the exercise price is higher than
the fair value per share during the year.
2. Comparative figures
Certain comparative figures have been reclassified to conform with the
current year's presentation.
|
